NEW YORK, June 7, 2019 /PRNewswire/ — Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that positive study results have been published in the Journal of Clinical Investigation (JCI) Insight1. These results show FractalDx portfolio technology can accurately predict early acute kidney rejection in transplant patients. …